Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: Selective inactivation of P450 3A4

Drug Metabolism and Disposition

Volumn 30, Issue 9, 2002, Pages 985-990

  Khan, Kishore K ^a   He, You Qun ^b   Correia, Maria Almira ^a   Halpert, James R ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MIFEPRISTONE; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; HORMONE ANTAGONIST; RECOMBINANT PROTEIN;

ARTICLE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME MECHANISM; HYDROXYLATION; OXIDATION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; CHEMISTRY; DRUG ANTAGONISM; GENETICS; OXIDATION REDUCTION REACTION;

CYTOCHROME P-450 ENZYME SYSTEM; HORMONE ANTAGONISTS; MIFEPRISTONE; MUTAGENESIS, SITE-DIRECTED; OXIDATION-REDUCTION; RECOMBINANT PROTEINS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0036707616     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.9.985     Document Type: Article

References (39)

1. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver, cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine
2. RU486 (mifepristone): Mechanisms of action and clinical uses
3. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450
4. Mifepristone
5. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450
6. Analysis of mammalian cytochrome P450 structure and function using site-directed mutagenesis
7. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and the effect on substrate oxidation and cooperativity
8. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: Role in steroid hydroxylase activity and alpha-naphthoflavone stimulation
9. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes
10. i values and impact of CYP3A5 expression
11. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
12. Reversal of multidrug resistance by RU 486
13. Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity
14. Structure and function of cytochromes P450: A comparative analysis of three crystal structures
15. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)
16. Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis
17. Pharmacokinetics of the antiprogesterone RU 486: No correlation to clinical performance of RU 486
18. The genetic determinants of the CYP3A5 polymorphism
19. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes
20. Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes
21. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation
22. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
23. The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function
24. Mechanism-based inactivation of cytochrome P450 3A4 by L-754, 394
25. Differential effects of naturally occurring isothiocyanates on the activities of cytochrome P450 2E1 and the mutant P450 2E1 T303A
26. Membrane binding and substrate access merge in cytochrome P450 7A1, a key enzyme in degradation of cholesterol
27. In vitro metabolism of quinidine: The (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes
28. Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates
29. Putative helix F contributes to regioselectivity of hydroxylation in mitochondrial cytochrome P450 27A1
30. Structural studies on prokaryotic cytochrome P450s, in Cytochrome P450
31. Crystal structure of substrate-free Pseudomonas putida cytochrome P-450
32. Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: Identification of an active-site peptide
33. Inactivation of cytochrome P450s 2B1, 2B4, 2B6 and 2B11 by arylalkynes
34. 3H-labeled 2-ethynylnaphthalene-inactivated P450 2B1-and 2B4 using amino acid sequencing and mass spectrometry
35. A role for threonine 302 in the mechanism-based inactivation of P450 2B4 by 2-ethynylnaphthalene
36. 1 metabolism as a probe
37. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3)
38. Identification of a polymorphically expressed member of the human cytochrome P-450III family
39. 1 oxidation